CRISPR-Cas13b approach silences oncogenic fusion transcripts in cell models
Start here
A team at Peter MacCallum Cancer Centre has published a proof-of-concept study in Science Advances describing a CRISPR-Cas13b method that recognizes and silences nine oncogenic fusion transcripts, including BCR-ABL1 and EWSR1-FLI1. The approach works by targeting fusion breakpoint sequences, allowing it to distinguish fusion genes from their normal counterparts. The researchers note that gene fusions of the kind targeted are found in roughly one in five cancers. The work so far has been completed only in cell models, and testing in animal models or patients has not yet been reported.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- Medical XpressPickNew CRISPR approach targets gene fusions found in 1 in 5 cancers
A Peter MacCallum Cancer Centre team has published a study in Science Advances using CRISPR-Cas13b to recognize and silence nine oncogenic fusion transcripts, including BCR-ABL1 and EWSR1-FLI1, by their fusion breakpoint sequences. The work is a proof of concept completed only in cell models.
Coverage and heat for this story
Reports so far 1·Heat now 6·Peak heat 10 (Oct 19 22:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.